Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast vs Adalimumab in Psoriatic Arthritis
NCT07398651Not yet recruiting
- Sponsor
- Tanta University
- Start
- Dec 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Trial of apremilast and adalimumab in psoriatic arthritis (PsA) (2 arms), sponsored by Tanta University. Primary endpoint: Disease Activity Index for Psoriatic Arthritis at 3 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
apremilastadalimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07398651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07398651.